Acute Kidney Injury – Epidemiology – Mature Markets
Clarivate Epidemiology's coverage of acute kidney injury comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan).
The populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology's acute kidney injury forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of acute kidney injury over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate’s Epidemiology forecasts the following AKI patient populations:
- Diagnosed AKI events
- Diagnosed AKI events requiring dialysis.
Note: coverage may vary by country.
Table of contents
- Acute Kidney Injury - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Event Estimates of Acute Kidney Injury per 1,000 People of All Ages in 2021 and 2031
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Events of Acute Kidney Injury over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Events of Acute Kidney Injury over the Next 20 Years
- Epidemiology data
- Key Findings
- Epidemiology data
- Methods
- Diagnosed AKI events
- Diagnosed AKI events requiring dialysis
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Acute Kidney Injury
- Studies Excluded from the Analysis of Acute Kidney Injury
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.